| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Jun-30-17 | Jun-30-16 | Jun-30-15 |
| | 10-K | 10-K | 10-K | 10-K | 8-K | 10-K | 10-K | 10-K |
| Revenues: |
| Clinical Development | | | | 9.5 | | 0.5 | 0.6 | |
| Device | 9.3 | 9.5 | | 9.5 | | 14.0 | 11.3 | |
| Related Distributor | | | | | | 0.3 | | |
| Distributor | | | | | | 1.0 | | |
| Other | | 0.2 | | | | | | |
| Total revenues | 9.3 | 9.7 | 13.0 | 9.7 | 12.8 | 14.5 | 11.9 | 16.0 |
| Revenue growth [+] | -4.6% | -25.3% | 34.9% | -24.2% | | 21.8% | -25.6% | 0.3% |
| Clinical Development | | | | | | -23.8% | | |
| Device | -2.4% | | | | | 24.4% | | |
| Cost of goods sold | 5.8 | 8.5 | 7.4 | 7.5 | 7.7 | 8.7 | 9.2 | 11.3 |
| Gross profit | 3.5 | 1.3 | 5.7 | 2.2 | 5.1 | 5.8 | 2.7 | 4.7 |
| Gross margin | 37.6% | 12.9% | 43.7% | 22.7% | 39.6% | 40.2% | 23.0% | 29.6% |
| Selling, general and administrative [+] | 8.5 | 7.7 | 8.0 | 9.6 | 1.7 | 12.4 | 10.4 | 13.7 |
| Sales and marketing | | | 1.7 | 1.4 | 1.7 | 1.5 | 2.1 | 3.0 |
| General and administrative | | | 6.4 | 8.3 | | 10.9 | 8.2 | 10.7 |
| Research and development | 2.2 | 2.5 | 2.4 | 3.0 | 3.4 | 2.5 | 3.2 | 5.9 |
| Equity in earnings | | | 0.0 | | | | | |
| Other operating expenses | | | | | 8.2 | | | |
| EBITDA [+] | -6.6 | -8.2 | -3.9 | -9.8 | | -8.2 | -9.7 | -13.5 |
| EBITDA growth | -19.1% | 106.8% | -59.7% | 19.7% | | -15.1% | -28.2% | 67.9% |
| EBITDA margin | -71.0% | -83.7% | -30.2% | -101.3% | -64.1% | -56.7% | -81.3% | -84.2% |
| Depreciation | 0.6 | 0.7 | 0.7 | 0.5 | | 0.5 | 0.7 | 0.9 |
| EBITA | -7.2 | -8.9 | -4.6 | -10.3 | -8.2 | -8.7 | -10.4 | -14.4 |
| EBITA margin | -77.8% | -91.3% | -35.4% | -106.8% | -64.1% | -59.9% | -87.4% | -89.8% |
| Amortization of intangibles | | | 0.1 | 0.1 | | 0.4 | 0.4 | 0.5 |
| EBIT [+] | -7.2 | -8.9 | -4.7 | -10.5 | -8.2 | -9.1 | -10.9 | -14.9 |
| EBIT growth | -18.7% | 87.3% | -54.6% | 27.9% | | -16.6% | -26.9% | 64.4% |
| EBIT margin | -77.8% | -91.3% | -36.4% | -108.2% | -64.1% | -62.4% | -91.1% | -92.6% |
| Non-recurring items [+] | | | | 33.1 | 0.3 | 0.3 | | |
| Asset impairment | | | | 33.1 | 0.3 | 0.3 | | |
| Interest expense | 6.1 | 7.9 | 4.5 | 2.7 | 0.7 | 20.5 | 1.9 | 0.0 |
| Interest expense | 6.1 | 7.9 | 4.5 | 2.7 | 0.7 | 20.5 | 1.9 | 0.0 |
| Other income (expense), net [+] | 1.5 | 0.0 | -0.9 | 0.6 | 0.2 | 0.1 | -5.9 | 0.0 |
| Amortization of financing costs and debt discount | | | | | | | -6.1 | |
| Gain (loss) on debt retirement | -0.7 | | -0.8 | | | | -0.8 | |
| Gain (loss) on derivative instruments | | | 0.0 | 0.6 | | -0.1 | 3.4 | |
| Other | | | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 |
| Pre-tax income | -11.9 | -16.8 | -10.1 | -45.7 | -8.9 | -29.8 | -18.6 | -14.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | -4.7 | -2.9 | -0.7 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 10.4% | 32.6% | 2.3% | 0.0% | 0.0% |
| Minority interest | -0.5 | -0.5 | -0.6 | -1.2 | | | | |
| Net income | -11.4 | -16.4 | -9.5 | -39.7 | -6.0 | -29.1 | -18.6 | -14.9 |
| Net margin | -122.4% | -167.8% | -72.8% | -410.6% | -47.2% | -200.3% | -155.8% | -92.6% |
| |
| Basic EPS [+] | ($0.96) | ($2.60) | ($3.36) | ($21.57) | ($0.61) | ($3.27) | ($7.57) | ($7.36) |
| Growth | -63.0% | -22.4% | -84.4% | 3464.8% | | -56.8% | 2.8% | 1966.9% |
| Diluted EPS [+] | ($0.96) | ($2.60) | ($3.36) | ($21.57) | ($0.61) | ($3.27) | ($7.57) | ($7.36) |
| Growth | -63.0% | -22.4% | -84.4% | 3464.8% | | -56.8% | 2.8% | 1966.9% |
| |
| Shares outstanding (basic) [+] | 11.8 | 6.3 | 2.8 | 1.8 | 10.0 | 8.9 | 2.5 | 2.0 |
| Growth | 87.9% | 121.9% | 53.6% | -81.5% | | 262.6% | 21.7% | -91.7% |
| Shares outstanding (diluted) [+] | 11.8 | 6.3 | 2.8 | 1.8 | 10.0 | 8.9 | 2.5 | 2.0 |
| Growth | 87.9% | 121.9% | 53.6% | -81.5% | | 262.6% | 21.7% | -91.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |